Table 1.
Healthcare Provider (HCP) Survey (n=501)
| HCP and Practice Characteristics | |
| Clinical practice setting, n (% [95% CI]) | |
| Academic-based | 40 (8.0 [5.8, 10.7]) |
| Community-based | 80 (16.0 [12.9, 19.5]) |
| Private practice | 416 (83.0 [79.5, 86.2]) |
| Size of practice, n (% [95% CI]) | |
| Solo (1 ophthalmologist or optometrist) | 104 (20.8 [17.3, 24.6]) |
| Small (2–10 ophthalmologists or optometrists) | 312 (62.3 [57.9, 66.5]) |
| Medium (11–50 ophthalmologists or optometrists) | 78 (15.6 [12.5, 19.0]) |
| Large (≥51 ophthalmologists or optometrists) | 7 (1.4 [0.6, 2.9]) |
| Number of years in practice, n (% [95% CI]) | |
| <1 year | 2 (0.4 [0.0, 1.4]) |
| 1–5 years | 60 (12.0 [9.3, 15.1]) |
| 6–10 years | 118 (23.6 [19.9, 27.5]) |
| 11–20 years | 170 (33.9 [29.8, 38.3]) |
| >20 years | 151 (30.1 [26.1, 34.4]) |
| Number of unique DED patients seen per year | |
| Mean ± SD [median] (95% CI of mean) | 393.0 ± 304.5 [300.0] (366.3, 419.7) |
| Percentage of unique DED patients seen per year treated with lifitegrast | |
| Mean ± SD [median] (95% CI of mean) | 20.3 ± 20.7 [14.0] (18.5, 22.1) |
| Treatment Practices | |
| Timing of lifitegrast prescription, n (% [95% CI]) | |
| After DED diagnosis and prior to prescribing other therapies treating symptoms of DED | 68 (13.6 [10.7, 16.9]) |
| After DED diagnosis and in combination with other therapies treating symptoms of DED | 180 (35.9 [31.7, 40.3]) |
| Following treatment with other therapies treating DED symptoms | 253 (50.5 [46.0, 55.0]) |
| Average time between DED diagnosis and lifitegrast prescription, n (% [95% CI]) | |
| <1 month | 38 (7.6 [5.4, 10.3]) |
| 1–3 months | 154 (30.7 [26.7, 35.0]) |
| 4–6 months | 198 (39.5 [35.2, 44.0]) |
| 7–12 months | 63 (12.6 [9.8, 15.8]) |
| 1–2 years | 31 (6.2 [4.2, 8.7]) |
| >2 years | 17 (3.4 [2.0, 5.4]) |
| Reasons for lifitegrast prescription, n (% [95% CI])a | |
| Efficacy | 288 (57.5 [53.0, 61.9]) |
| Immediate relief of symptoms | 137 (27.3 [23.5, 31.5]) |
| Improvement in signs | 151 (30.1 [26.1, 34.4]) |
| Tolerability | 138 (27.5 [23.7, 31.7]) |
| Patient preference | 76 (15.2 [12.1, 18.6]) |
| Insurance coverage | 148 (29.5 [25.6, 33.7]) |
| Failure of other treatments | 267 (53.3 [48.8, 57.7]) |
| Otherb | 2 (0.4 [0.0, 1.4]) |
Notes: aHCPs were allowed to select more than one category. bOther reasons for prescription included “coupon use making it more affordable” and “plugs”.
Abbreviations: CI, confidence interval; HCP, healthcare provider; SD, standard deviation.